GSK Taps Cellzome For Inflammatory Disease Deal
This article was originally published in The Pink Sheet Daily
Executive SummaryGSK will pay Cellzome £14.4 million upfront for options to Kinobeads drug candidates.
You may also be interested in...
GlaxoSmithKline tries to turn partnerships into acquisitions with varying results, as one company accepts a buy-out while another adopts a poison-pill strategy.